Vivace Therapeutics, a San Mateo, CA-based small molecule discovery and development company, raised $35M in Series D funding.
The round was led by RA Capital Management, an existing investor, and included investment from other existing investors Canaan Partners and Cenova Capital. In conjunction with the financing, Jake Simson, Ph.D., partner at RA Capital Management, has joined the company’s board of directors.
The company intends to use the funds to support the continued clinical development of the its transcriptional enhanced associate domain (TEAD) autopalmitoylation inhibitor, VT3989, with an initial focus on mesothelioma.
Led by Sofie Qiao, Ph.D., president and chief executive officer, Vivace Therapeutics is a small molecule drug discovery and development company focused on targeting the Hippo pathway. VT3989 is a novel small molecule cancer therapeutic that targets the Hippo pathway by inhibiting palmitoylation of members of the TEAD protein family. The compound has been evaluated in more than 150 patients to date in an ongoing, open-label Phase 1 clinical study and is the first and only member of the TEAD autopalmitoylation inhibitor class for which compelling clinical efficacy data have been publicly reported. In addition to promising efficacy, VT3989 has demonstrated excellent safety in the Phase 1 trial, positioning the compound with a profile.
FinSMEs
12/03/2025